Participants
Screening for study eligibility occurred within 28 days prior to the first dose administration. Healthy males or females of any ethnic origin, aged 18–55 years for Part A and 18–60 years for Part B, weighing ≥ 50 kg with a body mass index (BMI) of 18.0–32.0 kg/m